Company / R&D Expense
Nuvalent, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$307.0M
FY2025
5-year range
$35.6M / $307.0M
FY2021-FY2025
Trend
+41.0%
vs FY2024
Sector context
#59 of 210
Health Care
What the data says
At $307M, Nuvalent, Inc.'s r&d expense ranks #59 of 210 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $15M in FY2020 to $307M in FY2025.
Based on SEC 10-K filings.
$307M in FY2025 with a 5-year CAGR of +81.9%.
Improved from $113M to $307M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +68.9%
- 5-Year CAGR
- +81.9%
- 10-Year CAGR
- -
Sector benchmark
#59 of 210 in Health CareTop 28% of 210This company $307.0M Sector average $644.1M
▼
-52.3% below sector average
Key checks
Key Insights
- Nuvalent, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +81.9%, indicating consistent growth.
- In FY2025, r&d expense increased 41.0% year-over-year.
- Ranks #59 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $307.0M | +41.0% |
| FY2024 | $217.8M | +92.3% |
| FY2023 | $113.2M | +77.7% |
| FY2022 | $63.7M | +79.2% |
| FY2021 | $35.6M | +130.9% |
| FY2020 | $15.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026